HIKMA PHARMACEUTICALS PLC ('Hikma') announces that it has purchased the following number of its ordinary shares on the London Stock Exchange, Aquis Stock Exchange Limited and CBOE Europe Limited through the BXE and CXE order books from Morgan Stanley & Co. International plc ('Morgan Stanley'). The repurchased shares will be cancelled.

Contact:

Hikma Pharmaceuticals PLC

Peter Speirs

Company Secretary

T: +44 (0)20 7399 2772

Susan Ringdal

EVP Strategy and Global Affairs

T: +44 (0)20 7399 2760

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.

(C) 2022 Electronic News Publishing, source ENP Newswire